Prognostičko značenje citoredukcije kod raka jajnika - iskustvo iz istočne Hrvatske
| Autor: | Margareta Ugljarević, Zlatko Topolovec, Domagoj Vidosavljević, Stjepan Topolovec, Siniša Šijanović, Teodora Horvat, Dimitrije Milojković, Andrijana Müller-Vranješ |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Adult
Oncology medicine.medical_specialty Neoplasm Residual Ovarijski tumori Citoredukcijski kirurški postupci Prognoza Retrospektivne studije Kemoterapija adjuvantna Hrvatska Croatia medicine.medical_treatment Carcinoma Ovarian Epithelial Ovarian neoplasms Cytoreduction surgical procedures Prognosis Retrospective studies Chemotherapy adjuvant Cytoreduction Surgical Procedures Internal medicine Ascites medicine Ascitic Fluid Humans Stage (cooking) Original Scientific Papers Aged Neoplasm Staging Aged 80 and over Univariate analysis Chemotherapy business.industry Proportional hazards model Age Factors Retrospective cohort study General Medicine Middle Aged medicine.disease Survival Rate Parity Female Neoplasm Grading medicine.symptom Ovarian cancer business |
| Zdroj: | Acta Clinica Croatica Acta clinica Croatica Volume 58. Issue 2. |
| ISSN: | 1333-9451 0353-9466 |
| Popis: | The aim of this retrospective study was to present the impact of successful optimal cytoreductive therapy on the overall prognosis of ovarian cancer treatment. Several factors were analyzed, including clinical (stage, age and parity), histopathologic/cytological (histologic type and grade of tumors, cytological findings of ascites or peritoneal washout), and therapeutic (surgery performed with the degree of cytoreduction, adjuvant chemotherapy and response to therapy). The study included 126 patients treated during a 5-year period at the Department of Gynecology and Obstetrics, Osijek University Hospital Centre in Osijek. Patient age ranged from 29 to 82, total 5-year survival was 55.5% and median survival was 76.2 months. Optimal cytoreduction (residual tumor Cilj ove retrospektivne studije bio je prikazati utjecaj optimalne citoreduktivne terapije na ukupnu prognozu liječenja raka jajnika. Analizirano je nekoliko čimbenika uključujući kliničke (stupanj, dob i paritet), histopatološke/citološke (histološki tip i stupanj tumora, citološki nalaz ascitesa ili peritonealnog ispiranja) i terapijske značajke (operativni zahvat sa stupnjem citoredukcije, adjuvantne kemoterapije i odgovora na terapiju). U istraživanju je sudjelovalo 126 bolesnica liječenih tijekom petogodišnjeg razdoblja na Klinici za ginekologiju i opstetriciju Kliničkog bolničkog centra u Osijeku. Dob bolesnica bila je u rasponu od 29 do 82 godine, ukupno petogodišnje preživljavanje bilo je 55,5%, a medijan preživljenja 76,2 mjeseca. Optimalna citoredukcija (rezidualni tumor |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|